1[1]Grundmann K,Jaschonek K,Kleine B,et al.Aspirin non-responder status in patients with recurrent cerebral ischemic attacks[J].J Neurol,2003,250(1):63-66.
2[2]Charles H Hennekens,Karsten Schror,Steven Weisman,et al.Terms and conditions:semantic complexity and aspirin resistance[J].Circulation,2004,110:1706-1708.
3[3]Macchi L,Christiaens L,Brabant S,et al.Resistance in vitro to low-dose aspirin is associated with platelet PlA1 (GP Ⅲa) polymorphism but not with C807T(GP Ⅰa/Ⅱa) and C-5T Kozak (GP Ⅰb alpha) polymorphisms[J].J Am Coll Cardiol,2003 42(6):1115-1119.
4[4]Ridker PM,Cook NR,Lee IM,et al.A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women[J].N Engl J Med,2005,352:1293-1304.
5[5]The Medical Research Council's General Practice Research Framework.Thrombosis prevention trial:randomised trial of lowintensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischemic heart disease in men at increased risk[J].Lancet,1998,351:233-241.
6[6]Kjeldsen SE,Kolloch RE,Leonetti G,et al.Influence of gender and age on preventing cardiovascular disease by antihypertensive treatment and acetylsalicylic acid:the HOT study[J].J Hypertens,2000,18:629-642.
7[7]Pignone M,Earnshaw S,Tice JA,et al.Aspirin,statins,or both drugs for the primary prevention of coronary heart disease events in men:a cost-utility analysis[J].Ann Intern Med,2006,144(5):326-336.
8[8]U.S.Preventive Services Task Force.Aspirin for the primary prevention of cardiovascular events:recommendations and rationale[J].Am Fam Physician,2002,65(10):2107-2110.
9[9]Berger JS,Roncaglioni MC,Avanzini F,et al.Aspirin for the primary prevention of cardiovascular events in women and men a sex-specific meta-analysis[J].JAMA,2006,295(3):306-313.
10[10]European Society of Cardiology,European Atherosclerosis Society,European Society of Hypertension,International Society of Behavioural Medicine,European Society of General Practice/Family Medicine,European Heart Network Prepared by David Wood,Guy De Backer,Ole Faergeman,Ian Graham,Giuseppe Mancia and Kalevi Pyorala¨ together with members of the Task Force.Prevention of coronary heart disease in clinical practice:recommendations of the second joint task force of European and other societies on coronary prevention[J].Eur Heart J,1998,1434-1503.
2Lanas A,Pere2-Aisa MA,Feu F,et al.Investigators of the Asociacion Espanola de Gastroenterologia(AEG).A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with nonsteroidal antiinflammatory drug uee[J].Am J Gastroenterol,2005,100(8):1665-1693.
3Yeornans ND.New data on healing of nonsteroidal antlinflammatory drug-associated ulcers and erosions[J].Omeprazole NSAID Steering Committee[J].Am J Med,1998,104(3A):569-616,discussion 798-808.
4Wilcox C M,Clark WS.Association of nonsteroidal antiinflammatory drugs with outcome in upper and lower gastrointestinal bleeding[J].Dig Dis Sci,1997,42(5):985-989.
5Coppell MS,Schein JR.Diagnosis and treatment of nonsteroidal antiinflammatory drug-associated upper gastrointestinal toxicity[J].Gastroenterol Clin North Am,2000,29(1):97-124.
6Ono S,Kato M,Asaka M,et al.Diagnostic imaging of NSAID ulcers[J].Nippon Rinsho,2007,65(10):1792-1800.
7Gleeson M H,Lim S H,Spencer D.Non-steroidal anti-inflammatory drugs,salicylates,and colitis[J].Lancet,1996,347(9005):904-905.
8Bulluck H, Kwok CS, Ryding AD, et al. Safety of short- term dual antiplatelet therapy after drug-eluting stents: an updated meta-analysis with direct and adjusted indirect comparison of randomized control trials[J], Int J Cardiol, 2014,181C:331.
9Gilard M, Barragan P, Noryani AA, et al. Six-month ver- sus 24-month dual antiplatelet therapy after implantation of drug eluting stents in patients non-resistant to aspirin: ITALIC, a randomized multicenter trial[J]. JAm Coil Car- diol, 2015,65(8) : 777.
10E1-Hayek G, Messerli F, Bangalore S, et al. Meta-analy- sis of randomized clinical trials comparing short-term ver- sus long-term dual antiplatelet therapy following drug- eluting stents [J]. Am J Cardiol, 2014,114 ( 2 ) : 236.
